Injecto Polymers IPO Day 1: Subscribed 0.25x; QIB surges to 1.02x late in day
- Injecto Polymers IPO subscribed 0.25x on Day 1
- QIB demand surged to 1.02x in the final hour
- Retail participation rose to 0.17x
- Issue priced between ₹98 and ₹100 per share
- Subscription window closes on September 16, 2026

*this image is generated using AI for illustrative purposes only.
Injecto Polymers IPO subscription surged to 0.25x on Day 1, driven by a late spike in Qualified Institutional Buyer (QIB) demand. QIBs accounted for 1.02x of the total subscription, while retail investors contributed 0.17x. The issue remains open for bidding until September 16, 2026.
Subscription Status
The injection molding company’s public issue saw significant momentum in the afternoon session on Day 1. Total demand ticked up to 0.25x by the end of trading, marking a sharp acceleration from the morning levels. Qualified Institutional Buyers (QIBs) emerged as the dominant category, contributing 1.02x to the overall subscription after remaining flat earlier in the day. Retail investors also showed increased interest, with their subscription rising to 0.17x. Non-Institutional Investors (NII) participation remained modest, with bHNI at 0.10x and sHNI at 0.02x.
Intra-day Timeline
Subscription activity picked up pace sharply in the final hour of trading. The total subscription jumped from 0.09x at 14:15 PM to 0.25x by 15:15 PM, driven primarily by institutional investor interest.
| Time (IST) | QIB | NII (bHNI) | Retail | Total |
|---|---|---|---|---|
| 12:15 | 0.00x | 0.02x | 0.07x | 0.04x |
| 13:15 | 0.00x | 0.02x | 0.08x | 0.06x |
| 14:15 | 0.00x | 0.02x | 0.15x | 0.09x |
| 15:15 | 1.02x | 0.02x | 0.17x | 0.25x |
Subscription Progression
The following table outlines the end-of-day subscription status for Day 1.
| Day | Date | QIB | NII (bHNI) | NII (sHNI) | Retail | Total |
|---|---|---|---|---|---|---|
| Day 1 | 11-09-2026 | 1.02x | 0.02x | 0.10x | 0.17x | 0.25x |
Offer Details
Injecto Polymers has priced its IPO between ₹98 and ₹100 per share. The minimum bid quantity is set at 2,400 shares. The issue size ranges from ₹235,200 lakh to ₹500,000 lakh depending on the final price discovery.
- Price Band: ₹98 - ₹100
- Issue Size: ₹235,200 lakh - ₹500,000 lakh
- Min Bid Qty: 2,400 shares
- Open Date: 2026-09-11
- Close Date: 2026-09-16
About the Company
Injecto Polymers Limited is a packaging company engaged in manufacturing diverse packaging products including Polypropylene Woven Fabrics, PP Woven Bags, BOPP bags, FIBC bags, and non-woven bags. The company also trades plastic granules and PVC resins. It operates two manufacturing units in West Bengal with a combined installed capacity of 18,070 MT. The company serves customers across agriculture, construction, textiles, chemicals, and consumer goods industries through a B2B model. Promoters Ramesh Kumar Rateria and Ashok Kumar Rateria bring 65 years of combined industry experience.
Financial Highlights
The company reported revenue from operations of ₹375.53 crores for FY26, up from ₹261.48 crores in FY25. Profit after tax stood at ₹16.01 crores in FY26, compared to ₹8.11 crores in FY25.
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| Revenue from Operations (₹ cr) | 375.53 | 261.48 | 109.05 |
| Profit After Tax (₹ cr) | 16.01 | 8.11 | 4.44 |
| Total Assets (₹ cr) | 270.93 | 170.57 | 121.25 |
Objects of the Issue
- Repayment/pre-payment of certain outstanding borrowings: ₹10.00 crores
- Funding Capital expenditure for Phase IV expansion at existing manufacturing facility: ₹30.50 crores
- General Corporate Purposes: Balance proceeds
Risk Factors
- High Customer Concentration: Top 10 customers contributed 40.07% of FY26 revenue.
- Dependence on Trading Activities: Trading contributed 50.36% of FY26 revenue.
- Geographic Concentration: 85.27% of FY26 revenue generated from West Bengal.
- Raw Material Supply and Price Volatility: Dependence on polypropylene and other raw materials.
- Negative Operating Cash Flows: Reported negative operating cash flows in FY26, FY25, and FY24.
Will the late-day QIB surge indicate sustained institutional confidence, or is it likely to be followed by profit-booking pressure once the stock lists?
How might Injecto Polymers' heavy reliance on trading activities (over 50% of revenue) impact its valuation multiples compared to pure-play manufacturing peers?
Given the negative operating cash flows over the last three years, how will investors assess the company's ability to service debt after utilizing IPO proceeds for repayment and capex?
























